NCT06038526View on ClinicalTrials.gov

Evaluation of Canakinumab in High-Risk Former-Smokers

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cigarette Smoking-Related CarcinomaLung Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo buccal, nasal, and blood sample collection

PROCEDURE

Bronchoscopy

Undergo bronchoscopy

BIOLOGICAL

Canakinumab

Given SC

PROCEDURE

Carbon Monoxide Measurement

Undergo CO testing

OTHER

Survey Administration

Ancillary studies

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Peter Shields

OTHER